Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MIRA Pharmaceuticals Inc

MIRA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.76

▲ +5.52%

Market Cap $31.91M · Vol 32.91K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$31.91M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

48.71

Momentum

Beta

N/A

vs Market

52W High

$2.44

70.51% below

52W Low

$0.61

17.60% above

Volume

32.91K

Avg 43.33K

P/B

6.09

Price-to-book

ROE

N/A

Return on equity

Free Float

69.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, MIRA Pharmaceuticals Inc (MIRA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MIRA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.79%

-3.89%

-22.38%

-35.10%

YTD

-49.72%

-41.14%

-74.86%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-10,442,490.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-149.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	6.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	42.02M

Technical Indicators

50-Day SMA	$0.80
200-Day SMA	$1.08
RSI (14)	48.71
Beta	N/A
52-Week High	$2.44
52-Week Low	$0.61

Volume Today	32.91K
Avg Daily Volume (30D)	43.33K
Relative Volume	0.76x
Volatility (10D)	80.98
Volatility (30D)	77.02
Free Float	69.42%

Analyst Consensus

N/A

Current Price $0.76

Mean Target N/A

52W Low$0.61 52W High$2.44

Current

Target

$0.61 $2.44

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG01H8XP681

ISINUS60458C1045

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.